Role of T790M Mutation in EGFR-TKI Rechallenge for Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer

被引：0
|
作者：
Zhang, Qiu-Yi [1 ,2 ,3 ]
Ke, E-E [1 ,2 ,3 ]
Deng, Wei [1 ,2 ,3 ]
Niu, Fei-Yu [1 ,2 ,3 ]
Zhao, Ning [1 ,2 ,3 ]
Su, Jian [3 ,4 ]
Chen, Zhi-Hong [3 ,4 ]
Yang, Jin-Ji [1 ,2 ,3 ]
Xu, Chong-Rui [1 ,2 ,3 ]
Yan, Hong-Hong [1 ,2 ,3 ]
Wu, Yi-Long [1 ,2 ,3 ]
Zhou, Qing [1 ,2 ,3 ]
机构：
[1] Guangdong Lung Canc Inst, Guangzhou, Guangdong, Peoples R China
[2] Guangdong Gen Hosp GGH, Guangzhou, Guangdong, Peoples R China
[3] Guangdong Acad Med Sci, Guangzhou, Guangdong, Peoples R China
[4] Guangdong Gen Hosp GGP, Med Res Ctr, Guangzhou, Guangdong, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2015年 / 10卷 / 09期
关键词：
non-small cell lung cancer; EGFR-TKIs; T790M; Rechallenge;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MINI03.09
引用
收藏
页码：S271 / S271
页数：1
相关论文
共 50 条
  • [1] EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer
    Otsuka, Kyoko
    Hata, Akito
    Takeshita, Jumpei
    Okuda, Chiyuki
    Kaji, Reiko
    Masago, Katsuhiro
    Fujita, Shiro
    Katakami, Nobuyuki
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 76 (04) : 835 - 841
  • [2] EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer
    Kyoko Otsuka
    Akito Hata
    Jumpei Takeshita
    Chiyuki Okuda
    Reiko Kaji
    Katsuhiro Masago
    Shiro Fujita
    Nobuyuki Katakami
    [J]. Cancer Chemotherapy and Pharmacology, 2015, 76 : 835 - 841
  • [3] The role of T790M mutation in EGFR-TKI re-challenge for patients with EGFR-mutant advanced lung adenocarcinoma
    Zhang, Qiuyi
    Ke, Ee
    Niu, Feiyu
    Deng, Wei
    Chen, Zhihong
    Xu, Chongrui
    Zhang, Xuchao
    Zhao, Ning
    Su, Jian
    Yang, Jinji
    Yan, Honghong
    Wu, Yilong
    Zhou, Qing
    [J]. ONCOTARGET, 2017, 8 (03) : 4994 - 5002
  • [4] Association of EGFR Exon 19 Deletion and EGFR-TKI Treatment Duration with Frequency of T790M Mutation in EGFR-Mutant Lung Cancer Patients
    Matsuo, Norikazu
    Azuma, Koichi
    Sakai, Kazuko
    Hattori, Satoshi
    Kawahara, Akihiko
    Ishii, Hidenobu
    Tokito, Takaaki
    Kinoshita, Takashi
    Yamada, Kazuhiko
    Nishio, Kazuto
    Hoshino, Tomoaki
    [J]. SCIENTIFIC REPORTS, 2016, 6
  • [5] Association of EGFR Exon 19 Deletion and EGFR-TKI Treatment Duration with Frequency of T790M Mutation in EGFR-Mutant Lung Cancer Patients
    Norikazu Matsuo
    Koichi Azuma
    Kazuko Sakai
    Satoshi Hattori
    Akihiko Kawahara
    Hidenobu Ishii
    Takaaki Tokito
    Takashi Kinoshita
    Kazuhiko Yamada
    Kazuto Nishio
    Tomoaki Hoshino
    [J]. Scientific Reports, 6
  • [6] Association of EGFR Exon 19 Deletion and EGFR-TKI treatment duration with Frequency of T790M Mutation in EGFR-Mutant Lung Cancer Patients
    Matsuo, Norikazu
    Azuma, Koichi
    Sakai, Kazuko
    Kawahara, Akihiko
    Ishii, Hidenobu
    Tokito, Takaaki
    Kinoshita, Takashi
    Yamada, Kazuhiko
    Nishio, Kazuto
    Hoshino, Tomoaki
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1201 - S1202
  • [7] Spatiotemporal T790M Heterogeneity in Individual Patients with EGFR-Mutant Non-Small-Cell Lung Cancer after Acquired Resistance to EGFR-TKI
    Hata, Akito
    Katakami, Nobuyuki
    Yoshioka, Hiroshige
    Kaji, Reiko
    Masago, Katsuhiro
    Fujita, Shiro
    Imai, Yukihiro
    Nishiyama, Akihiro
    Ishida, Tadashi
    Nishimura, Yoshihiro
    Yatabe, Yasushi
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (11) : 1553 - 1559
  • [8] Safety and activity of alflutinib in patients with advanced EGFR T790M mutation non-small cell lung cancer who progressed after EGFR-TKI therapy
    Shi, Y-K.
    Zhang, S.
    Hu, X.
    Feng, J.
    Ma, Z.
    Zhou, J.
    Yang, N.
    Wu, L.
    Liao, W.
    Han, X.
    Wang, Z.
    Zhang, X.
    Qin, S.
    Ying, K.
    Feng, J.
    Fang, J.
    Liu, L.
    Jiang, Y.
    [J]. ANNALS OF ONCOLOGY, 2019, 30 : 629 - 629
  • [9] Non-invasive and quantitative analysis for EGFR T790M mutation in the patients with advanced non-small cell lung cancer received EGFR-TKI therapy.
    Chen, Rui
    An, Tongtong
    Wang, Jie
    Bai, Hua
    Wang, Zhijie
    Zhao, Jun
    Wu, Meina
    Zhuo, Minglei
    Duan, Jianchun
    Wang, Yuyan
    Wang, Shuhang
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [10] Furmonertinib for EGFR-mutant advanced non-small cell lung cancer: a glittering diamond in the rough of EGFR-TKI
    Ding, Jianghua
    Ding, Xingjing
    Zeng, Jiao
    Liu, Xiaoqun
    [J]. FRONTIERS IN PHARMACOLOGY, 2024, 15
12345